Embracing AI while Keeping an Eye Out for Fraud 
ScienceLogic™ Cuts Complexity and Accelerates IT Performance with Skylar™ One Updates 
Embracing the Three ‘R’s of Quantum 
Stockman’s Casino Selects Quick Custom Intelligence Enterprise Platform G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023
RESEARCH TRIANGLE PARK, N.C., July 26, 2023 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX),…
G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023
RESEARCH TRIANGLE PARK, N.C., July 26, 2023 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX),…
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
AUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company…
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
AUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company…
Yield10 Bioscience Files Request for Regulatory Status Review under USDA-APHIS’s SECURE Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil
Camelina containing the omega-3 EPA trait Camelina containing the omega-3 EPA trait growing at acre-scale…
Yield10 Bioscience Files Request for Regulatory Status Review under USDA-APHIS’s SECURE Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil
Camelina containing the omega-3 EPA trait Camelina containing the omega-3 EPA trait growing at acre-scale…
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif.,…
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif.,…
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., July 26, 2023 (GLOBE…
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., July 26, 2023 (GLOBE…
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVYâ„¢ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis
SHANGHAI, China and PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) — LianBio’s (Nasdaq: LIAN) partner,…
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVYâ„¢ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis
SHANGHAI, China and PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) — LianBio’s (Nasdaq: LIAN) partner,…
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
FREMONT, CA, July 26, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:…
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
FREMONT, CA, July 26, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:…
CorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023
BERKELEY HEIGHTS, N.J., July 26, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
CorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023
BERKELEY HEIGHTS, N.J., July 26, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases
– Kriya’s therapeutic pipeline addresses a broad range of diseases that collectively affect millions of…
Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases
– Kriya’s therapeutic pipeline addresses a broad range of diseases that collectively affect millions of…
Recce Pharmaceuticals Doses Subjects in Rapid Infusion Phase I/II UTI Clinical Trial of RECCE® 327 at Scientia Clinical Research
Dosing at Scientia Clinical Research has commenced with first male and female subjects dosed ahead…
Recce Pharmaceuticals Doses Subjects in Rapid Infusion Phase I/II UTI Clinical Trial of RECCE® 327 at Scientia Clinical Research
Dosing at Scientia Clinical Research has commenced with first male and female subjects dosed ahead…